Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-18
2008-09-23
Weddington, Kevin E (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S400000, C514S419000, C514S423000, C514S556000, C514S557000, C514S561000, C514S562000
Reexamination Certificate
active
07427619
ABSTRACT:
Pharmaceutical compositions effective in alleviating or reducing the effects of fatigue and weakness associated with cancer and cancer chemotherapy are disclosed. The pharmaceutical compositions of the present invention comprise riboflavin, effectors of the urea cycle in free form or pharmacologically acceptable salts thereof, and amino acids selected from the groups of essential and non-essential amino acids, in free form or pharmaceutically acceptable salts thereof, suitably combined with appropriate carriers, diluents, or excipients. Also disclosed are methods of alleviating or reducing the effects of fatigue and weakness associated with cancer and cancer chemotherapy by administration of pharmaceutical compositions of the present invention.
REFERENCES:
patent: 4826680 (1989-05-01), Jaeger
patent: 5045468 (1991-09-01), Darfler
patent: 5430064 (1995-07-01), Hirsch et al.
patent: 5547927 (1996-08-01), Cope et al.
patent: 5550146 (1996-08-01), Acosta et al.
patent: 5656608 (1997-08-01), Schneider et al.
patent: 5719134 (1998-02-01), Schmidl et al.
patent: 5776913 (1998-07-01), Ogilvie et al.
patent: 5817695 (1998-10-01), Pellico
patent: 6337094 (2002-01-01), Guardiola et al.
patent: 0 747 395 (1996-12-01), None
patent: 2 029 220 (1980-03-01), None
Kulcsár, G. “Inhibition of the Growth of a Murine and Various Human Tumor Cell Lines in Culture and in Mice by Mixture of Certain Substances of the Circulatory System”Cancer Biotherapy, 10: 157-176 (1995).
Cascino, A., et al. “Plasma Amino-Acids in Human Cancer: the Individual Role of Tumour, Malnutrition and Glucose Tolerance”Clinical Nutrition, 7: 213-218 (1988).
Cole, N., et al. “Character of Terminal Illness in the Advanced Cancer Patient: Pain and Other Symptoms During the Last Four Weeks of Life”J. Pain Symptom Management, 5: 83-93 (1990).
McGeer, A.J., et al. “Parenteral Nutrition in Patient Receiving Cancer Chemotherapy”Annals o fInternal Medicine, 110: 734-736 (1989).
Koretz, R.L. “Parental Nutrition: Is It Oncologically Logical?”J. Clinical Oncology, 2: 534-538 (1984).
Breitbart, W., et al. “Pemoline: An Alternative Psychostimulant for the Management of Depressive Disorders in Cancer Patients”Psychosomatics, 33: 352-356 (1992).
Baron, P.L., et al. “Effects of Parenteral Nutritional on Cell Cycle Kinetics of Head and Neck Cancer”Arch. Surgery, 121: 1282-1286 (1986).
Reynolds, J.V., et al. “Immunologic Efects of Arginine Supplementation in Tumor-Bearing and Non-Tumor-Bearing Hosts”Ann. Surgery, 211: 202-210 (1990).
Reynolds, J.V., et al. “Argine, Protein Malnutrition, and Cancer”J. Surgical Res., 45: 513-522 (1988).
Barbul, A. “Arginine: Biochemistry, Physiology, and Therapeutic Implications”J. Parenteral Enteral Nutrition, 10: 227-238 (1986).
Tachibana, K., et al. “Evaluation of the Effects of Arginine-Enriched Amino Acid Solution on Tumor Growth”J. Parenteral Enteral Nutrition, 9: 428-434 (1985).
Heyland, D.K., et al. “Total Parenteral Nutrition in the Critically III Patient: A Meta-Analysis”J. Am. Med. Assoc., 280: 2013-2019 (1998).
Vachon, M.L.S., et al. “Psychosocial Issues Palliative Care: the Patient, the Family, and the Process and Outcome of Care”J. pain Symptom Management, 10: 142-150 (1995).
Braga, M., et al. “Perioperative Immunonutrition in Patients Undergoing Cancer Surgery”Arch. Surgery, 134: 428-433 (1999).
Cozzaglio, L., et al. “Does Parenteral Nutrition Increase Tumor Growth? A Review”Tumori, 80: 169-174 (1994).
Muscaritoli, M., et al. “Plasma Amino Acid Concentrations in Patients with Acute Myelogenous Leukemia”Nutrition, 15: 195-199 (1999).
Wheeler, M.D., et al. “Glycine: A New Anti-Inflammatory Immunonutrient”Cell. Mol. Life Sciences, 56: 843-856 (1999).
Redmond, H.P., et al. “Immunonutrition: The Role of Taurine”Nutrition, 14: 599-604 (1998).
Rivlin, R.S. “Riboflavin and Cancer: A Review”Cancer Research, 33: 1977-1986 (1973).
Rivlin, R.S., et al. “Effects of Riboflavin Deficiency Upon Concentrations of Riboflavin, Flavin Mononucleotide, and Flavin Adenine Dinucleotide in Novikoff Hepatoma in Rats”Cancer Research, 33: 3019-1023 (1973).
Rivlin, R.S. “Riboflavin”Adv. Exp. Med. Biol. 206: 349-355 (1986).
Chaudhry, M., et al. “The Vitamin D3 analog, ILX-23-7553, Enhances the Response to Adriamycin and Irradiation in MCF-7 Breast Tumor Cells.”Cancer Chemother, Pharmacol. 47: 429-436 (2001).
Liau, M.C., et al. “Riboflavin as a Minor Active Anticancer Component of Antieoplaston A2 and A5”Int. J. Tissue Reac. 12: 19-?? (1990).
Wargovich, M. J., et al. “Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression”Carcinogenesis, 21: 1149-1155, (2000).
Wersinger, C., et al. “Detailed study of the different taurine uptake systems of colon LoVo MDR and non-MDR cell lines”Amino Acids, 19: 667-685 (2000).
Grossie, V. B., Jr., et al. “Substituting Ornithine for Arginine in Total Parenteral Nutrition eliminates Enhanced Tumor Growth”J. of Surgical Oncology, 50: 161-167, (1992).
Grossie, V. B., Jr., et al. “A Parenteral Nutrition Regimen With Ornithine Substituted for Arginine Alter the Amino Acid, bu Not Polyamine, Content of the Ward Colon Tumor”Nutrition and Cancer, 27: 102-106 (1997).
Bruera, E. et al. “Psychstimulants as Adjuvant Analegesics”Journal of Pain and Symptom Management, 9: 412-415 (1994).
Chance, et al., “Reduction of Tumor Growth Following Treatment with a Glutamine Antimetabolite”Life Sciences42(1) (1988) 87-94 (abstract).
Synold, et al., “Role of Folypolyglutamate Synthetase (FPGS) in Antifolate Chemotherapy; a Biochemical and Clinical Update”,Leukemia&Lymphoma21 (1-2) (1996) 9-15 (abstract).
Ronald R. Koertz, “Parental Nutrition: Is it Oncologically Logical?”Journal of Clinical Oncology, vol. 2, No. 5, may 1984, pp. 534-538.
Copeland J.A. et al., “Inhibition of Estrogen Stimulated Mitogenesis by 3-Phenylacetylamino-2,6-Piperdinedione and its Para-Hydroxy Analog”,Journal of Steroid Biochemistry and Molecualr Biology, 46(4):451-462 (1993) (abstract).
Burzynski, S.R. et al., “Toxicology Studies on Oral Formulation of Antineoplaston A10 in Cancer patients”,Drugs Under Experiments and Clinical Research, 10:611-619 (1984) (abstract).
Howrey LLP
Weddington Kevin E
LandOfFree
Formulation of amino acids and riboflavin useful to reduce... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulation of amino acids and riboflavin useful to reduce..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation of amino acids and riboflavin useful to reduce... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3988908